WO2014148847A1 - 히알루론산의 제조방법 및 상기 제조방법으로 제조된 히알루론산을 포함하는 유착방지용 조성물 - Google Patents
히알루론산의 제조방법 및 상기 제조방법으로 제조된 히알루론산을 포함하는 유착방지용 조성물 Download PDFInfo
- Publication number
- WO2014148847A1 WO2014148847A1 PCT/KR2014/002364 KR2014002364W WO2014148847A1 WO 2014148847 A1 WO2014148847 A1 WO 2014148847A1 KR 2014002364 W KR2014002364 W KR 2014002364W WO 2014148847 A1 WO2014148847 A1 WO 2014148847A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- million
- present
- adhesion
- molecular weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Definitions
- the present invention relates to a method for preparing hyaluronic acid having a low decomposition rate in the body, and a composition for preventing adhesion, which includes hyaluronic acid prepared by the above method, and specifically, a straptococcus disgalactia 9103 strain (KCTC11818BP) is used as a carbon source and
- the present invention relates to a method for preparing hyaluronic acid having a low decomposition rate in a body including culturing in a medium containing a nitrogen source, and a composition for preventing adhesion of hyaluronic acid prepared by the above method.
- Hyaluronic acid (HA), Hyaluronan, (C14H20NNa011) n (n> 1000)) is a macromolecule present in the body and is a polysaccharide called glycosaminoglycan.
- the structure is a structure in which D-glucuronic acid and N-acetylglucosamine are repeatedly connected by -1,3 and -1,4 bonds. It is a water-soluble substance, has a very high viscosity, high elasticity, and has a wide range of linear polysaccharides ranging from 1, 000-10, 000, 000 Da (daltons).
- hyaluronic acid Since hyaluronic acid has a strong moisturizing effect, it has a strong lubricating function under physical friction, and has a very desirable advantage in physical properties such as protection against bacteria and invasion. Very much.
- biological tissue extraction method or microbial culture method are basically used, but recently, due to many disadvantages such as virus invasion, impurities, and inflammatory reaction, it is possible to control molecular weight and productivity rather than chicken crest extraction method and to obtain high quality raw materials.
- Possible microbial culture production methods are the trend. In particular, the development trend is determined according to the molecular weight range of hyaluronic acid produced by being controlled by microbial culture.
- Ultra-low molecular weight hyaluronic acid below 100,000 Da is mainly used for food and cosmetics.
- the low molecular weight hyaluronic acid with an average molecular weight of 1 million Da is also used as an eye drop material or derivative development target, and the average molecular weight of 3 million to 4 million Da and hyaluronic acid are highly useful as a raw material for injecting knee joints.
- its use as an ophthalmic surgical aid is increasing, and as the ultra-high molecular weight in the body, it is attracting attention as a raw material of anti-adhesion agent.
- Adhesion is usually found in the healing process of inflammation, which is caused by entanglement of granules or scars with each other or large amounts of precipitated fibrin. In general, adhesions occur at a frequency of 67 ⁇ 93% after open surgery, and some of them are spontaneously decomposed, but in most cases, adhesions exist even after wound healing (Eur. J. Surg 1997) , Suppl 577, 32-39). In order to prevent this, the development of anti-adhesion agents that physically and chemically block the occurrence of adhesions with surrounding tissues by covering the wound after surgery or pharmacological action, etc. is being developed worldwide.
- anti-adhesion agents are made by using various polymer materials, and alginic acid, CMC, and hyaluronic acid are mainly used, and hyaluronic acid is a hyaluronic acid crosslinked material that has increased molecular weight, viscosity, or elasticity by using low molecular weight hyaluronic acid. have.
- the anti-adhesion agent is sold as a film type product, but it is difficult to spread the thin film and it is difficult to use one product in different parts. It was developed as a gel-type product, and it is used to squeeze it with a syringe on the surgical site.
- the polymer material is used because it can be lowered, and in the case of hyaluronic acid, most crosslinked ones are used.
- the most problematic in using the crosslinked hyaluronic acid as a raw material of the anti-adhesion agent is the compound used for crosslinking, and the compound used for crosslinking even after hyaluronic acid is decomposed as an in vivo material is present in the body. There is a possibility of staying and causing side effects.
- Korean Patent No. 10-1074467 prepared the anti-adhesion agent by mixing L-arginine and hyaluronic acid, Korean Patent No. 10-0374666 and In Korean Unexamined Patent Application Publication No. 10-2011-0114810, hyaluronic acid gel for preventing adhesion was made using sodium hyaluronate, which is a kind of hyaluronic acid salt.
- Korean Patent Publication No. 10-2009- 0012439 used a hyaluronic acid cross-linked by mixing a hyaluronic acid and a crosslinking agent.
- US6630167 prepared an anti-adhesion agent by mixing a hyaluronic acid aqueous solution with a crosslinking agent solution. Therefore, in the domestic and foreign conventional technology, do not crosslink or The use of unaltered hyaluronic acid alone has not been found, and the use of hyaluronic acid alone is negative in most domestic and foreign prior arts. This was mostly.
- the present inventors have a long retention period in the body, and while searching for a method of developing hyaluronic acid that is effective in preventing adhesion, the hyaluronic acid prepared using the Straptococcus disgalactia 9103 strain has an excellent anti-adhesion effect due to the slow decomposition rate in the body. Discovered to complete the present invention.
- an object of the present invention is to provide a method for producing hyaluronic acid having a low degradation rate in the body, comprising culturing the S. aureus 9103 strain (KCTC11818BP) in a medium containing a carbon source and a nitrogen source.
- KCTC11818BP S. aureus 9103 strain
- Another object of the present invention is to provide a composition for preventing adhesion, which is prepared by the method for preparing hyaluronic acid of the present invention and which has no crosslinked hyaluronic acid as an active ingredient.
- Another object of the present invention is to provide a method for preventing adhesion, which is prepared by the method for preparing hyaluronic acid of the present invention and comprises administering uncrosslinked hyaluronic acid to a subject in need thereof.
- Another object of the present invention is to provide a hyaluronic acid prepared by the method for producing hyaluronic acid of the present invention and used for preventing crosslinking that is not crosslinked.
- the present invention provides a method for producing hyaluronic acid having a low degradation rate in the body comprising culturing Streptococcus disgalactia 9103 strain (KCTC11818BP) in a medium containing a carbon source and a nitrogen source.
- KCTC11818BP Streptococcus disgalactia 9103 strain
- the present invention is prepared by a method for producing hyaluronic acid, and provides an anti-adhesion composition comprising a non-crosslinked hyaluronic acid as an active ingredient.
- the method for producing hyaluronic acid of the present invention It is to provide an anti-adhesion method comprising the step of administering the hyaluronic acid prepared and not cross-linked to a subject in need thereof.
- the present invention provides a hyaluronic acid prepared by the method for preparing hyaluronic acid of the present invention and used for preventing crosslinking without crosslinking.
- the present invention provides a method for producing hyaluronic acid having a low degradation rate in a body comprising culturing Streptococcus disgalactia 9103 strain (KCTC11818BP) in a medium containing a carbon source and a nitrogen source.
- KCTC11818BP Streptococcus disgalactia 9103 strain
- step (b) may be a manufacturing method comprising the step of recovering hyaluronic acid from the culture cultured in step (a).
- the Streptococcus disgalactia 9103 strain of the present invention isolates a strain that produces microbial hyaluronic acid isolated from bovine feces, followed by mutation. It does not produce hyaluronic acid degrading enzymes, and it is a microorganism that is selected to be non-hemolytic.
- Streptococcus disgalactia ID9103 strain of the present invention can be cultured by a conventional culture method of Streptococcus microorganisms.
- the medium may be a medium including a carbon source and a nitrogen source, and may further include amino acids or metal ions.
- the carbon source of the present invention may be any carbon source used for culturing known microorganisms, and preferably, may be selected from the group consisting of glucose, fructose, maltose, yudan, galactose, glycerol and combinations thereof. More preferably, it may be maltose.
- the nitrogen source of the present invention may be any nitrogen source used for culturing known microorganisms, preferably yeast extract, casein peptone, casein acid digest, casein enzyme digest, bactopeptone, kaziton, neopeptone and combinations thereof It may be selected from the group consisting of. More preferably, it may be a casein enzyme digest.
- the casein enzymatic digestion refers to the enzymatic digestion of casein, for example, tryptone, tryptic tee, trypton extract, BB biosepteptone, diphcocazeingest, victocaziton, bibitriptase kinase peptone, bactote Lipton, Vitek Trypton, Engamine A, Engamine A, Engamine AK, Engamine L Concentration, Eng Case, Eng Case M, Eng Case M, Eng Case Plus, Engage T, Peptase, Trip Ton E. sp., Pancreatic hydrolysis caseincodex, pancreatic hydrolysis casein, enzymatic digestion caseincosher, trypton v.
- the medium of the present invention may further comprise amino acids or metal ions.
- the amino acid is not limited in kind, and preferably may be selected from the group consisting of glutamine, lysine, cysteine, arginine, methionine, aspartic acid, glycine, and combinations thereof. More preferably arginine.
- the metal ion is not limited in its kind, but may be preferably selected from the group consisting of sodium potassium, calcium, magnesium, iron, zinc, manganese and mixtures thereof, more preferably zinc. have.
- the medium composition of the present invention may be one containing a casein enzyme decomposition product as a nitrogen source, arginine as an amino acid, and zinc as a metal ion.
- a casein enzyme decomposition product as a nitrogen source
- arginine as an amino acid
- zinc as a metal ion.
- the casein enzyme digest and the concentration of arginine and zinc are not particularly limited, the casein enzyme digest is included at a concentration of 0.53 ⁇ 4 (w / v) to 3% (w / v), arginine is (0.01) % (w / v) to 0.6% (w / v), zinc is preferably included at a concentration of (0.01)% (w / v) to 0.1% (w / v).
- the culture method of the present invention is not particularly limited, and may be, for example, batch, fed-batch, or continuous culture.
- the culture method of the present invention may preferably be a fed-batch culture method.
- the medium component fed in a fed-batch may be a nitrogen source or a nitrogen source and a carbon source, the nitrogen source may be a casein enzyme digest, and the carbon source may be more preferably maltose.
- the step of recovering hyaluronic acid in the production method of the present invention may be by a method for separating the active substance from a known microbial culture, specifically, the sterilization process, neutralization process or crystallization process, chromatography or By centrifugation Endotoxin, proteins, nucleic acids, metals, and the like, and removal and purification of impurities and the like.
- the hyaluronic acid prepared by the hyaluronic acid production method of the present invention is not limited thereto, but preferably may be a high molecular hyaluronic acid having an average molecular weight of 3.5 million Da to 10 million Da.
- all the average molecular weights described in this invention are a weight average molecular weight.
- the production method of the present invention can produce a high yield of hyaluronic acid of a polymer having a limited average molecular weight.
- hyaluronic acid having a molecular weight of 4.43 million Da to 5.59 million Da and an amount of production of 8.07 g / L to 9.42 g / L was manufactured by the method of the present invention, thereby obtaining a high amount of hyaluronic acid having a high yield and molecular weight ( See Table 1).
- the low degradation rate of the body of the present invention refers to a slow rate of decomposition of hyaluronic acid after administration to the body.
- the experiment was carried out in the body degradation rate of hyaluronic acid produced by the production method of the present invention.
- the hyaluronic acid enzyme that decomposes hyaluronic acid in the body is treated with hyaluronic acid to measure the viscosity by molecular weight (3 million Da, 4 million Da, 6 million Da) over time.
- the value (cP) was measured.
- the hyaluronic acid having a molecular weight of 4 million Da and 6 million Da was lower in viscosity decrease over time than the hyaluronic acid of 3 million Da.
- the low viscosity reduction rate means that the decomposition of hyaluronic acid proceeds slowly in the body to maintain the viscosity of hyaluronic acid at a constant level. Accordingly, hyaluronic acid having a molecular weight of 4 million Da or more manufactured by the method of the present invention may have a low decomposition rate in the body, and preferably, hyaluronic acid having a molecular weight of 4 million Da to 6 million Da is an anti-adhesion effect. May be excellent.
- Hyaluronic acid prepared by the production method of the present invention may have a molecular weight of 3.5 million Da to 10 million Da, preferably 4 million Da to 10 million Da, more preferably 4 million Da to 6 million Da Hyaluronic acid having a molecular weight of less than 3.5 million Da Acid is difficult to expect the anti-adhesion effect due to the fast decomposition rate in the body, it is difficult to manufacture hyaluronic acid having a molecular weight of 10 million Da or more. Therefore, hyaluronic acid prepared by the production method of the present invention has a low decomposition rate in the body.
- the anti-adhesion composition comprising the hyaluronic acid as an active ingredient is a slow decomposition rate in the body, it is excellent in the anti-adhesion effect.
- the present invention is prepared by the production method of the present invention, and provides an anti-adhesion composition comprising non-crosslinked hyaluronic acid as an active ingredient.
- the present invention provides a method for preventing adhesion, which is prepared by the production method of the present invention and comprises the step of administering uncrosslinked hyaluronic acid to a subject in need thereof.
- the present invention provides hyaluronic acid prepared by the method for preparing hyaluronic acid of the present invention and used for preventing crosslinking that is not crosslinked.
- the present invention also provides an anti-adhesion agent comprising the hyaluronic acid of the present invention as an active ingredient.
- the anti-adhesion agent of the present invention is characterized by comprising the hyaluronic acid of the present invention, and may further include a saline solution, distilled water, a complete solution of sodium phosphate.
- the hyaluronic acid of the present invention can be used as an anti-adhesion agent because it shows a lubricating effect for preventing time-bound adhesion even in the state of not being crosslinked due to a slow decomposition rate in the body compared to the conventional hyaluronic acid.
- the non-crosslinked hyaluronic acid refers to hyaluronic acid prepared by the production method of the present invention that does not contain a chemical crosslinking agent, a chemical modifier, and a cationic polymer forming a complex with the hyaluronic acid.
- the chemical crosslinking agent is a compound that reacts with hyaluronic acid to form a three-dimensional network structure.
- a polyvalent epoxy compound such as polyglycidyl ether, a divinyl sulfone, formaldehyde, phosphorus oxychloride, a carbodiimide compound and an amino acid ester And a combination of a carbodiimide compound and a dihydrazide compound.
- the chemical modifier is a compound that forms a covalent bond with a carboxyl group, a hydroxyl group, or a setamido group of hyaluronic acid, a combination of acetic anhydride and concentrated sulfuric acid, a combination of anhydrous trifluoroacetic acid and an organic acid, and an alkyl iodine compound. It may be one or more compounds selected from the group consisting of.
- the cationic polymer that forms a complex with the hyaluronic acid is a polymer that forms a complex by ionic bonding between a carboxyl group of the hyaluronic acid and an amino group or an imino group of the polymer compound, chitosan, polylysine, polyvinylpyridine, polyethylene It may be one or more cationic polymer selected from the group consisting of imine and polydimethylaminoethyl methacrylate.
- the subject to which the anti-adhesion composition is administered may be an animal, preferably an animal including a mammal, particularly a human, or may be a cell, tissue, organ or the like derived from an animal.
- the subject may be a patient in need of treatment.
- administration can mean treatment by applying, spraying, or attaching an anti-adhesion agent containing hyaluronic acid as an active ingredient for the purpose of preventing adhesion to an object in need thereof.
- the anti-adhesion composition of the present invention can be administered anywhere in the body, but in dog abdominal surgery, gynecological surgery and thoracotomy, various magnetism, tendon membrane, cranial nerve, eye and eye, orthopedic surgery in the abdominal cavity and thoracic cavity, and tendons, ligaments and nerve It may be administered to the membrane in a surgical operation.
- the anti-adhesion composition of the present invention is not limited thereto, and may be used in the form of a gel, a film, and a film.
- the present invention provides a method for preparing hyaluronic acid having a low decomposition rate in the body and a composition for preventing adhesion of hyaluronic acid prepared by the above method.
- Hyaluronic acid produced by the production method of the present invention is a polymer hyaluronic acid of 3.5 million Da to 10 million Da, it is excellent in the prevention of adhesion due to the slow decomposition rate in the body.
- the anti-adhesion composition of the present invention comprising hyaluronic acid prepared by the production method of the present invention has an excellent anti-adhesion effect, and by using an uncrosslinked hyaluronic acid, the anti-adhesion composition containing an existing crosslinking agent and a compound has It is effective because it can improve the problems and problems of the existing hyaluronic acid.
- Figure 1 is a photograph of the state opened to see the difference in anti-adhesion efficacy according to the molecular weight.
- FIG. 2 is a view showing a decomposition rate of hyaluronic acid over time All.
- Y axis viscosity (cP)
- X axis min (in)
- SD rats (female, SPF, Orient Bio Co., Ltd.) were anesthetized by inhalation and continued to be anesthetized during surgery.
- the limbs were well fixed on the operating table, the abdominal hair was removed well with a razor, disinfectant was applied, and scissors were used to open the abdomen.
- the cecals were pulled out roughly: the gauze was used to scar the blood so that the gauze was buried, and the abdominal wall where the cecum was located also created the conditions for the cecal and peritoneal walls and adhesions.
- the sample was treated, sutured, bred for two weeks, and then opened to confirm adhesion.
- the sample was used by dissolving hyaluronic acid with an average molecular weight of 3 million Da and hyaluronic acid of 4 million Da and 6 million Da in a complete sodium phosphate solution, and maintained aseptic condition.
- This culture medium determination test for optimal production of hyaluronic acid was carried out in a 7.5L fermentation tank under 35L culture conditions.
- Medium composition was glucose 6) (w / v), yeast axle 0.5% (w / v), casein peptone 2% (w / v), glutamine 0.06% (w / v), sodium gluconate 0.1 (w / v) 0.02% (w / v), 0.05% (w / v) magnesium sulfate, 0.25% (w / v) dipotassium dihydrogen phosphate, 0.5% (w / v) sodium chloride, 0.5% (w / v) sodium acetate , Ferric chloride 0.007 (w / v), ammonium molybdenum 0.05 (w / v), and culture conditions were based on pH 7.0 and 34 conditions.
- Hyaluronic acid concentration present in the culture medium in the present invention is carbazole method (T. Bitter, Anal. Biochem., 1962, 4, 330-334) and turbidity analysis (S. Jung-Min, Carbohyd. Polym., 2009, 78, 633-634).
- the average molecular weight of hyaluronic acid was determined by gel filtration chromatography (Narlin B. Beaty et al, Anal. Biochem., 1985, 147, 387-395). The analysis conditions are as follows. The column used Toyo Soda TSK gel G6000 P3 ⁇ 4 L and the mobile phase is 150mM NaCl, 3mM Na2HP04 (pH7.0), 0.02% NaN 2 . Detect ion is a refrative index detector (Shodex;
- the concentration of hyaluronic acid produced under the culture conditions was 7 g / L, the molecular weight was measured to be 3 million Da.
- Arginine was added in place of glutamine, which is the basal medium, to show excellent results of more than 8.53 g / L and about 4.83 million Da in the production and molecular weight of hyaluronic acid.
- Carbon sources also play an important role in microbial growth and metabolism, as well as being used as precursors of hyaluronic acid. Therefore, it was determined that by changing the type of carbon source can affect the production of 4 million to 6 million Da hyaluronic acid.
- Metal ions are known to play various roles in the expression of DNA or the activity of enzymes in microbial cells. Therefore, various metal ions were tested in anticipation of affecting the activation and expression of enzymes or DNA involved in the production of hyaluronic acid.
- the zinc-added group produced 9.42 g / L and about 5.59 million Da molecular weight hyaluronic acid, showing excellent results.
- Table 1 The zinc-added group produced 9.42 g / L and about 5.59 million Da molecular weight hyaluronic acid, showing excellent results.
- the viscosity reduction rate (27.5%) of the hyaluronic acid of 3 million Da was significantly higher than that of 4 million Da and 6 million Da of hyaluronic acid.
- 4 million Da and 6 million Da hyaluronic acid compared to 3 million Da hyaluronic acid is about 3 to 4 times the viscosity decrease rate is lower than the rate of decomposition in the body can be seen, accordingly constant viscosity in the body It was confirmed to maintain the level.
- hyaluronic acid having a molecular weight of 4 million Da or more produced by the production method of the present invention has a low decomposition rate in the body, and preferably, hyaluronic acid having a molecular weight of 4 million Da to 6 million Da has an excellent anti-adhesion effect. .
- the present invention provides a method for preparing hyaluronic acid having a low decomposition rate in the body and a composition for preventing adhesion, which includes hyaluronic acid prepared by the above method.
- Hyaluronic acid produced by the production method of the present invention is a polymer hyaluronic acid of 3.5 million Da to 10 million Da, it is excellent in the prevention of adhesion due to the slow decomposition rate in the body.
- the anti-adhesion composition of the present invention comprising hyaluronic acid prepared by the production method of the present invention has a haze prevention adhesion effect
- the use of hyaluronic acid, which is not crosslinked, can improve the problems of the anti-adhesion composition containing the existing crosslinking agent and the compound and the problems of the existing hyaluronic acid, thereby increasing industrial applicability.
- the International Depositary has deposited the microorganisms indicated in item I of E and has received a request for transfer of the EFT to a deposit under the Budapest Treaty.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016504255A JP6370002B2 (ja) | 2013-03-20 | 2014-03-20 | ヒアルロン酸の製造方法及び前記製造方法で製造されたヒアルロン酸を含む癒着防止用組成物 |
CN201480029053.4A CN105324486B (zh) | 2013-03-20 | 2014-03-20 | 透明质酸的制造方法和含有通过上述制造方法制造的透明质酸的防粘连用组合物 |
EP14767484.0A EP2977460B1 (en) | 2013-03-20 | 2014-03-20 | Preparation method for hyaluronic acid, and anti-adhesive composition comprising hyaluronic acid prepared by same preparation method |
US14/859,975 US20160009828A1 (en) | 2013-03-20 | 2015-09-21 | Preparation method for hyaluronic acid, and anti-adhesive composition comprising hyaluronic acid prepared by same preparation method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130029876A KR101598329B1 (ko) | 2013-03-20 | 2013-03-20 | 히알루론산의 제조방법 및 상기 제조방법으로 제조된 히알루론산을 포함하는 유착방지용 조성물 |
KR10-2013-0029876 | 2013-03-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/859,975 Continuation US20160009828A1 (en) | 2013-03-20 | 2015-09-21 | Preparation method for hyaluronic acid, and anti-adhesive composition comprising hyaluronic acid prepared by same preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014148847A1 true WO2014148847A1 (ko) | 2014-09-25 |
WO2014148847A8 WO2014148847A8 (ko) | 2015-10-22 |
Family
ID=51580436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002364 WO2014148847A1 (ko) | 2013-03-20 | 2014-03-20 | 히알루론산의 제조방법 및 상기 제조방법으로 제조된 히알루론산을 포함하는 유착방지용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20160009828A1 (ko) |
EP (1) | EP2977460B1 (ko) |
JP (1) | JP6370002B2 (ko) |
KR (1) | KR101598329B1 (ko) |
CN (1) | CN105324486B (ko) |
WO (1) | WO2014148847A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975759B2 (en) | 2016-12-09 | 2021-04-13 | Cummins Inc. | Spark plug for an internal combustion engine having a combustion pre-chamber |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUA20164153A1 (it) | 2016-06-07 | 2017-12-07 | Jointherapeutics S R L | Composizioni polisaccaridiche impiegabili nella riparazione tissutale |
KR102489403B1 (ko) * | 2018-10-29 | 2023-01-17 | 엠앤에이치바이오 주식회사 | 신규한 스트렙토코커스 속 ubc-u46 균주 및 이를 이용한 히알루론산 생산 방법 |
EP3797800A1 (en) * | 2019-05-02 | 2021-03-31 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Hyaluronic acid hydrogels with prolonged antimicrobial activity |
KR102546437B1 (ko) * | 2021-03-15 | 2023-06-21 | 금오공과대학교 산학협력단 | 생체적합성 고분자를 포함하는 파우더형 유착방지제 및 그의 제조방법 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10113197A (ja) * | 1996-10-15 | 1998-05-06 | Chisso Corp | 高分子量ヒアルロン酸もしくはその塩の製造法 |
KR100374666B1 (ko) | 1997-08-22 | 2003-03-04 | 덴끼 가가꾸 고교 가부시키가이샤 | 히알루론산 겔, 그의 제조 방법 및 그를 함유하는 의학용재료 |
US6630167B2 (en) | 1999-07-28 | 2003-10-07 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
KR20090012439A (ko) | 2007-07-30 | 2009-02-04 | 주식회사 핸슨바이오텍 | 기관 유착 방지 특성을 갖는 히알루론산 및카르복시메칠셀룰로즈 복합체 유도체 필름 및 겔 및 그제조방법 |
KR20100048778A (ko) * | 2008-10-31 | 2010-05-11 | 일동제약주식회사 | 미생물 배양에 의한 히알우론산을 생산하는 방법 |
KR20100061963A (ko) * | 2008-12-01 | 2010-06-10 | 신풍제약주식회사 | 유착방지용 조성물 |
WO2010125069A1 (en) * | 2009-04-28 | 2010-11-04 | Pharmasurgics In Sweden Ab | Hyaluronic acid for preventing post surgical adhesions |
KR20110100364A (ko) | 2010-03-04 | 2011-09-14 | 신효산업 주식회사 | 2단 빨대 |
KR101074467B1 (ko) | 2009-05-08 | 2011-10-17 | 주식회사 휴메딕스 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
KR20110114810A (ko) | 2010-04-14 | 2011-10-20 | 황주환 | 다용도 압력 조리장치 |
WO2012057381A1 (ko) * | 2010-10-29 | 2012-05-03 | 주식회사 휴메딕스 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
KR20130025337A (ko) * | 2011-08-26 | 2013-03-11 | 주식회사 엘지생명과학 | 유착방지재 및 유착방지 방법 |
KR20130035808A (ko) * | 2011-09-30 | 2013-04-09 | 일동제약주식회사 | 스트렙토코커스 디스갈락티애 id9103 균주 및 이를 이용한 히알루론산 생산 방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
US5496726A (en) * | 1993-04-16 | 1996-03-05 | Lucky Limited | Streptococcus zooepidemicus medium and process for preparing hyaluronic acid |
AU2003252566A1 (en) * | 2002-08-19 | 2004-03-03 | Kolon Ind. Inc. | Microorganism producing hyaluronic acid and purification method of hyaluronic acid |
EP2031053A1 (en) * | 2007-08-31 | 2009-03-04 | The University Of Queensland | Production of HA |
WO2010010631A1 (ja) * | 2008-07-25 | 2010-01-28 | 電気化学工業株式会社 | ヒアルロン酸の製造方法 |
KR101132114B1 (ko) * | 2009-09-15 | 2012-04-05 | 일동제약주식회사 | 히알루론산의 분자량을 조절하는 방법 |
WO2011109130A1 (en) * | 2010-03-01 | 2011-09-09 | Tautona Group Lp | Threads of hyaluronic acid and methods of use thereof |
CN101912633A (zh) * | 2010-08-03 | 2010-12-15 | 孙伟庆 | 一种透明质酸海绵及其制备方法 |
-
2013
- 2013-03-20 KR KR1020130029876A patent/KR101598329B1/ko active IP Right Grant
-
2014
- 2014-03-20 WO PCT/KR2014/002364 patent/WO2014148847A1/ko active Application Filing
- 2014-03-20 EP EP14767484.0A patent/EP2977460B1/en active Active
- 2014-03-20 CN CN201480029053.4A patent/CN105324486B/zh active Active
- 2014-03-20 JP JP2016504255A patent/JP6370002B2/ja active Active
-
2015
- 2015-09-21 US US14/859,975 patent/US20160009828A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10113197A (ja) * | 1996-10-15 | 1998-05-06 | Chisso Corp | 高分子量ヒアルロン酸もしくはその塩の製造法 |
KR100374666B1 (ko) | 1997-08-22 | 2003-03-04 | 덴끼 가가꾸 고교 가부시키가이샤 | 히알루론산 겔, 그의 제조 방법 및 그를 함유하는 의학용재료 |
US6630167B2 (en) | 1999-07-28 | 2003-10-07 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
KR20090012439A (ko) | 2007-07-30 | 2009-02-04 | 주식회사 핸슨바이오텍 | 기관 유착 방지 특성을 갖는 히알루론산 및카르복시메칠셀룰로즈 복합체 유도체 필름 및 겔 및 그제조방법 |
KR20100048778A (ko) * | 2008-10-31 | 2010-05-11 | 일동제약주식회사 | 미생물 배양에 의한 히알우론산을 생산하는 방법 |
KR20100061963A (ko) * | 2008-12-01 | 2010-06-10 | 신풍제약주식회사 | 유착방지용 조성물 |
WO2010125069A1 (en) * | 2009-04-28 | 2010-11-04 | Pharmasurgics In Sweden Ab | Hyaluronic acid for preventing post surgical adhesions |
KR101074467B1 (ko) | 2009-05-08 | 2011-10-17 | 주식회사 휴메딕스 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
KR20110100364A (ko) | 2010-03-04 | 2011-09-14 | 신효산업 주식회사 | 2단 빨대 |
KR20110114810A (ko) | 2010-04-14 | 2011-10-20 | 황주환 | 다용도 압력 조리장치 |
WO2012057381A1 (ko) * | 2010-10-29 | 2012-05-03 | 주식회사 휴메딕스 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
KR20130025337A (ko) * | 2011-08-26 | 2013-03-11 | 주식회사 엘지생명과학 | 유착방지재 및 유착방지 방법 |
KR20130035808A (ko) * | 2011-09-30 | 2013-04-09 | 일동제약주식회사 | 스트렙토코커스 디스갈락티애 id9103 균주 및 이를 이용한 히알루론산 생산 방법 |
Non-Patent Citations (4)
Title |
---|
EUR. J. SURG., vol. 577, 1997, pages 32 - 39 |
NARLIN B. BEATY ET AL., ANAL. BIOCHEM., vol. 147, 1985, pages 387 - 395 |
S. JUNG-MIN, CARBOHYD. POLYM., vol. 78, 2009, pages 633 - 634 |
T. BITTER, ANAL. BIOCHEM., vol. 4, 1962, pages 330 - 334 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975759B2 (en) | 2016-12-09 | 2021-04-13 | Cummins Inc. | Spark plug for an internal combustion engine having a combustion pre-chamber |
Also Published As
Publication number | Publication date |
---|---|
JP6370002B2 (ja) | 2018-08-08 |
WO2014148847A8 (ko) | 2015-10-22 |
CN105324486B (zh) | 2020-09-01 |
KR20140115149A (ko) | 2014-09-30 |
JP2016515821A (ja) | 2016-06-02 |
CN105324486A (zh) | 2016-02-10 |
EP2977460A1 (en) | 2016-01-27 |
EP2977460A4 (en) | 2016-11-16 |
KR101598329B1 (ko) | 2016-02-29 |
EP2977460B1 (en) | 2019-05-08 |
US20160009828A1 (en) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5957096B2 (ja) | バチルス、ヒアルロン酸酵素、及びそれらの使用 | |
EP1753787B1 (en) | Method of covalently linking hyaluronan and chitosan | |
Schiraldi et al. | Biotechnological production and application of hyaluronan | |
WO2014148847A1 (ko) | 히알루론산의 제조방법 및 상기 제조방법으로 제조된 히알루론산을 포함하는 유착방지용 조성물 | |
CA2740136C (en) | Injectable in-situ crosslinked hydrogel and methods of making and using thereof | |
US8691793B2 (en) | Modified macromolecules and associated methods of synthesis and use | |
US20170014543A1 (en) | HYDROGEL BASED ON γ-POLYGLUTAMIC ACID AND ε-POLYLYSINE CROSSLINKED POLYMER, AND PREPARATION METHOD THEREFOR | |
Bam et al. | Design of biostable scaffold based on collagen crosslinked by dialdehyde chitosan with presence of gallic acid | |
CA2657162A1 (en) | Efficient process for purification of high molecular weight hyaluronic acid | |
KR20130057640A (ko) | 수불용성 겔 조성물 및 그 제조방법 | |
TR201802761T4 (tr) | Yüksek molekül ağırlıklı heparosan polimerler ve bunların üretimine ve kullanımına yönelik metotlar. | |
CN114502599A (zh) | 一种超支化聚甘油多缩水甘油醚及其作为多糖交联剂的用途 | |
US8664196B2 (en) | Shark-like chondroitin sulphate and process for the preparation thereof | |
CA2835691C (en) | Shark-like chondroitin sulphate and process for the preparation thereof | |
CN115429935B (zh) | 一种可注射性的交联硫酸软骨素水凝胶及其制备方法 | |
US20080194810A1 (en) | Method for Purifying Hyaluronic Acid Using Calcium Salt and Phosphate Salt, or Calcium Phosphate Salt | |
KR101087969B1 (ko) | 미생물 배양에 의한 히알우론산을 생산하는 방법 | |
Brekke et al. | Hyaluronan as a biomaterial | |
EP2581444B1 (en) | Deacetylation hydrolase of hyaluronic acid, hyaluronic acid deacetylated by same and derivative thereof | |
KR20120077726A (ko) | 히알루론산 및 그 염의 정제방법 | |
CN111588731A (zh) | 用于伤口愈合的组合物及其生成方法和用途 | |
Kumar et al. | 3 Biopolymers Applications in and Biomedicine Their | |
KR20220089586A (ko) | 복합기능성 유착방지용 약학조성물 | |
Kumar et al. | Biopolymers and Their Applications in Biomedicine | |
KR20220128790A (ko) | 생체적합성 고분자를 포함하는 파우더형 유착방지제 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480029053.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14767484 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016504255 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014767484 Country of ref document: EP |